DrugPatentWatch Database Preview
Drugs in Development Information for Rigosertib
» See Plans and Pricing
What is the drug development status for Rigosertib?
Rigosertib is an investigational drug.
There have been 29 clinical trials for Rigosertib.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Preleukemia, Myelodysplastic Syndromes, and Syndrome. The leading clinical trial sponsors are Onconova Therapeutics, Inc., Icahn School of Medicine at Mount Sinai, and The Leukemia and Lymphoma Society.
There are fifteen US patents protecting this investigational drug and ninety-six international patents.
Summary for Rigosertib
| US Patents | 15 |
| International Patents | 96 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 344 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2011-05-01) |
| Vendors | 28 |
Recent Clinical Trials for Rigosertib
| Title | Sponsor | Phase |
|---|---|---|
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Bristol-Myers Squibb | Phase 1/Phase 2 |
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Onconova Therapeutics, Inc. | Phase 1/Phase 2 |
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Icahn School of Medicine at Mount Sinai | Phase 1/Phase 2 |
Clinical Trial Summary for Rigosertib
Top disease conditions for Rigosertib
Top clinical trial sponsors for Rigosertib
US Patents for Rigosertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Rigosertib | Start Trial | Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones | ONCONOVA THERAPEUTICS, INC. (Newtown, PA) | Start Trial |
| Rigosertib | Start Trial | Substituted alkyl diaryl derivatives, methods of preparation and uses | TEMPLE UNIVERSITY--Of The Commonwealth System of Higher Education (Philadelphia, PA) | Start Trial |
| Rigosertib | Start Trial | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use | Temple University--Of The Commonwealth System Of Higher Education (Philadelphia, PA) | Start Trial |
| Rigosertib | Start Trial | Methods and compositions for treatment of cancer | ONCONOVA THERAPEUTICS, INC. (Newtown, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Rigosertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Rigosertib | Argentina | AR109503 | 2037-04-13 | Start Trial |
| Rigosertib | Australia | AU2018253291 | 2037-04-13 | Start Trial |
| Rigosertib | Brazil | BR112019021445 | 2037-04-13 | Start Trial |
| Rigosertib | Canada | CA3058664 | 2037-04-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
